



pISSN 2093-596X  ·  eISSN 2093-5978
Original
Article
Insulin Secretion and Insulin Resistance Trajectories over 1 
Year after Kidney Transplantation: A Multicenter 
Prospective Cohort Study
Jun Bae Bang1, Chang-Kwon Oh1, Yu Seun Kim2, Sung Hoon Kim3, Hee Chul Yu4, Chan-Duck Kim5, Man Ki Ju6, 
Byung Jun So7, Sang Ho Lee8, Sang Youb Han9, Cheol Woong Jung10, Joong Kyung Kim11, Su Hyung Lee1,  
Ja Young Jeon12
1Department of Surgery, Ajou University School of Medicine, Suwon; 2Department of Transplantation Surgery and Research 
Institute for Transplantation, Yonsei University College of Medicine, Seoul; 3Department of Surgery, Wonju Severance Christian 
Hospital, Yonsei University Wonju College of Medicine, Wonju; 4Department of Surgery, Jeonbuk National University Medical 
School, Jeonju; 5Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook 
National University, Daegu; 6Department of Surgery, Yonsei University College of Medicine, Seoul; 7Department of Surgery, 
Wonkwang University Hospital, Iksan; 8Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul; 
9Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang; 10Department of Surgery, Korea University 
College of Medicine, Seoul; 11Department of Internal Medicine, Bong Seng Memorial Hospital, Busan; 12Department of 
Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea
Background: We investigated the changing patterns of insulin secretion and resistance and risk factors contributing to the develop-
ment of post-transplant diabetes mellitus (PTDM) in kidney recipients under tacrolimus-based immunosuppression regimen during 
1 year after transplantation.
Methods: This was a multicenter prospective cohort study. Of the 168 subjects enrolled in this study, we analyzed a total 87 kidney 
transplant recipients without diabetes which was assessed by oral glucose tolerance test before transplantation. We evaluated the in-
cidence of PTDM and followed up the index of insulin secretion (insulinogenic index [IGI]) and resistance (homeostatic model as-
sessment for insulin resistance [HOMA-IR]) at 3, 6, 9 months, and 1 year after transplantation by oral glucose tolerance test and dia-
betes treatment. We also assessed the risk factors for incident PTDM.
Results: PTDM developed in 23 of 87 subjects (26.4%) during 1 year after transplantation. More than half of total PTDM (56.5%) 
occurred in the first 3 months after transplantation. During 1 year after transplantation, insulin resistance (HOMA-IR) was increased 
in both PTDM and no PTDM group. In no PTDM group, the increase in insulin secretory function to overcome insulin resistance 
was also observed. However, PTDM group showed no increase in insulin secretion function (IGI). Old age, status of prediabetes and 
episode of acute rejection were significantly associated with the development of PTDM.
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Conclusion: In tacrolimus-based immunosuppressive drugs regimen, impaired insulin secretory function for reduced insulin sensi-
tivity contributed to the development of PTDM than insulin resistance during 1 year after transplantation.
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INTRODUCTION
Post-transplant diabetes mellitus (PTDM), a common metabolic 
complication that occurs during the post-transplantation period, 
is associated with opportunistic infections, cardiovascular dis-
ease, and graft failure and poor survival in kidney transplant re-
cipients [1-5]. The incidence of PTDM after kidney transplanta-
tion ranges from 10% to 40%; recent cohort studies have shown 
that the 1-year incidence of PTDM is 10% to 15% in Asian 
populations [6,7]. High doses of immunosuppressive agents are 
administered to recipients in the early post-transplantation peri-
od, resulting in a high incidence of PTDM within the first 6 
months after transplantation. After 6 months, the dose and level 
of immunosuppressive agents are stabilized and the incidence 
of PTDM decreases to levels similar to those of non-transplant 
patients [8].
The oral glucose tolerance test (OGTT) is the gold standard 
test for diabetes; it is more accurate than fasting plasma glucose 
for the diagnosis of PTDM and types 1 and 2 diabetes [9,10]. 
However, the OGTT is not routinely performed in transplant re-
cipients because the test is not readily accessible in most trans-
plantation settings. Shabir et al. [11] suggested that the hemoglo-
bin A1c test could replace the OGTT as a diagnostic test for 
PTDM in the early post-transplantation period; however, their 
study sample size was relatively small. Despite difficulties in test 
administration, the OGTT remains an important tool for the de-
tection of PTDM. The recommended timing for the diagnosis of 
PTDM is at least 45 days after transplantation when the patients 
are receiving stable maintenance immunosuppression. A recent 
review recommended that the OGTT be performed at least 2 
months after transplantation for the diagnosis of PTDM [10,12]. 
 Given the numerous complications of PTDM, early detection 
and intervention is crucial. Modifiable risk factors (e.g., type 
and dose of immunosuppressive agent, graft ischemic time, and 
rejection episodes) can be managed by timely diagnosis and ap-
propriate intervention. Furthermore, analysis of insulin secre-
tion and insulin resistance is necessary to determine how immu-
nosuppressive agents interact with and affect PTDM [13]. Ta-
crolimus and corticosteroids, the immunosuppressive agents 
most commonly used after kidney transplantation, affect insulin 
secretion and insulin resistance, respectively, in dose-dependent 
manners [14]. Therefore, investigation of changes in the pat-
terns, or trajectories, of insulin secretion and resistance is im-
portant to determine their relative contributions to the develop-
ment of PTDM. Although several studies have used OGTTs to 
assess insulin secretion and resistance in kidney transplant re-
cipients, no studies have investigated the 1-year trajectories of 
insulin secretion and insulin resistance in kidney transplant re-
cipients receiving a tacrolimus-based regimen.
Here, we report the findings of a 1-year follow-up of 87 kid-
ney transplant recipients without pre-transplant diabetes and the 
1-year trajectories of insulin secretion and insulin resistance on 
a tacrolimus-based immunosuppression regimen. Furthermore, 
we used OGTT results to assess the incidences of and risk fac-
tors for PTDM. 
METHODS
Study population
This multicenter prospective cohort study (SERITAM [safety 
and efficacy of the step-wise reduction of immunosuppression 
with tacrolimus, mycophenolate mofetil, and basiliximab after 
kidney transplantation, and its effect on the glucose metabo-
lism]) included adult patients (aged 20 to 65 years) who re-
ceived kidney allografts from living or deceased donors be-
tween April 1, 2016 and September 31, 2018. The exclusion cri-
teria included multiple organ transplants, a double kidney trans-
plant, or organs donated after cardiac death; previous organ 
transplantation; ABO incompatibility; cross-match positivity; 
and a history of malignancy in the previous 5 years. In total, 168 
kidney transplant recipients met the inclusion criteria among 11 
centers. Among 168 recipients, 48 recipients were excluded due 
to pre-existing diabetes before transplantation, as determined by 
medical records. Furthermore, 33 recipients who had undiag-
nosed pre-transplant diabetes determined by the pre-transplant 
OGTT were excluded. After 81 recipients were excluded, the 
remaining 87 patients with normal pre-transplant glucose toler-
ance or prediabetes were included in the study and 1-year fol-
low-up analyses (Fig. 1). All patients enrolled in the study pro-
vided an informed consent, and the study protocol was approved 
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by the independent Institutional Review Board of each center 
(AJIRB-MED-CT4-15-422). 
Immunosuppressive regimen
The immunosuppressive regimen consisted of basiliximab 
(Simulect®, Novartis, Basel, Switzerland) as induction therapy, 
tacrolimus (TacroBell®, Chong Kun Dang, Seoul, Korea), myco-
phenolate mofetil (MY-REPT®, Chong Kun Dang Pharmaceuti-
cal Co., Seoul, Korea), and corticosteroids. Basiliximab was ad-
ministered immediately prior to transplantation and 4 days after 
transplantation. Tacrolimus was initiated 2 days before kidney 
transplantation at an initial dose of 0.05 to 0.1 mg/kg. The target 
tacrolimus trough level was between 5 and 12 ng/mL until 3 
months post-transplantation; the target level was then adjusted 
downward to between 3 and 8 ng/mL until the end of the fol-
low-up period. Corticosteroids were administrated intravenous-
ly at 500 mg on the day of transplantation, 250 mg on the day 
after transplantation; they were then gradually tapered to a 
maintenance dose of more than 5 mg a day of oral prednisone 
until 6 months post-transplantation. After 6 months, steroids 
were progressively reduced and stopped in a subset of recipients 
who were at low immunological risk. In patients who required 
steroid treatment due to immunological risk, steroids were ad-
ministered throughout the follow-up period. Mycophenolate 
mofetil was started within 72 hours of transplantation at a dose 
of 1.0 to 2.0 g/day. In patients who experienced leukopenia or 
gastrointestinal toxicity, mycophenolate mofetil dose reductions 
were managed in accordance with a defined protocol; they were 
guided by the clinical severity and course of the adverse event. 
Assessment of glucose metabolism, insulin secretion, and 
insulin resistance 
OGTT was performed at baseline and every 3 months after trans-
plantation until the end of the 1-year follow-up period in all pa-
tients. The patients were instructed to fast for at least 8 hours, 
and to not take oral hypoglycemic agents or inject insulin for 12 
hours. The patients were then given a drink containing 75 g glu-
cose mixed in water; plasma glucose and insulin were measured 
at 0, 30, and 120 minutes after glucose ingestion. In accordance 
with American Diabetes Association guidelines, PTDM was di-
agnosed when one of the following criteria was met: fasting 
plasma glucose, ≥126 mg/dL; 2-hour plasma glucose, ≥200 
mg/dL during OGTT; or requirement of oral hypoglycemic agent 
or insulin injection [15]. Prediabetes was defined as impaired 
fasting glucose (fasting plasma glucose, 100 to 125 mg/dL) and 
impaired glucose tolerance (OGTT 2-hour plasma glucose, 140 
to 199 mg/dL). OGTT results were used to assess the incidences 
of PTDM and prediabetes in all patients. 
The homeostatic model assessment for insulin resistance 
(HOMA-IR) was used to estimate insulin resistance by means 
of insulin levels derived from OGTTs, in accordance with an 
equation reported previously [16]. The insulinogenic index 
(IGI30), which was calculated from the insulin and glucose re-
sults of OGTTs performed at 0 and 30 minutes, was used to es-
timate insulin secretory function [17]. Additionally, Matsuda in-
dex and insulin secretion 1st phase (Secr1PH) were used to evalu-
ate insulin resistance and insulin secretion [18-20]. 
Statistical analysis
The cumulative incidence of PTDM was based on the results of 
OGTTs performed at the 1-year follow-up. The incidences of 
PTDM were assessed at the 3, 6, 9, and 12-month time-points. 
Categorical variables are expressed as a percentage of derived 
groups and were assessed using Pearson’s chi-square test and 
Fisher’s exact test. Continuous variables are expressed as mean± 
standard deviation or median with interquartile ranges, and were 
assessed using Student’s t test and the Mann-Whitney U test. 
Friedman rank sum test and Wilcoxon signed rank test were 
used to assess the HOMA-IR and IGI trajectories. Logistic re-
gression analysis was used to confirm independent risk factors 
for the development of PTDM. P values <0.05 were considered 
to indicate statistical significance. All statistical tests were per-
formed using SPSS Statistics version 20.0 (IBM Corp., Ar-
monk, NY, USA).
Adult kidney transplantation recipients
among 11 transplant centers (n=168)
Excluded (pre-transplant diabetes)
Prior existing diabetes (n=48)
Diabetes discovered by OGTT (n=33)
OGTT performed by every 3 months after
transplantation during 1-year
Eligible recipients (n=87)
No PTDM group (n=64) PTDM group (n=23)
Fig. 1. Patient selection figure. OGTT, oral glucose tolerance test; 
PTDM, post-transplant diabetes mellitus.
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RESULTS
PTDM incidence and baseline characteristics of recipients
Of the 87 recipients enrolled in the study, 48 (55.2%) were diag-
nosed with prediabetes, according to baseline OGTT results. 
During the follow-up period, the cumulative incidence of 
PTDM was 26.4% (n=23); 64 (73.6%) recipients exhibited nor-
mal pre-transplant glucose tolerance or prediabetes status. Three 
of the 23 recipients with PTDM received treatment for hyper-
glycemia. PTDM occurred within the first 3 months of trans-
plantation in 13 patients (56.5%), at 6 months in seven patients 
(30.4%), and at 9 months in three patients (13.0%). No new-on-
set PTDM was detected at the 12-month OGTT (Fig. 2). Of the 
64 recipients who did not develop PTDM during the study peri-
od, 35 exhibited normal pre-transplant glucose tolerance and 29 
recipients exhibited prediabetes status at 1 year after kidney 
transplantation. According to the OGTT results at 12 months, 
the prevalence of PTDM was 9.2% (n=8); 15 recipients diag-
nosed with PTDM before 12 months exhibited normal pre-
transplant glucose tolerance or prediabetes status.
The study participants were divided into two groups accord-
ing to PTDM status (Table 1). No significant between-group 
differences were found in terms of sex, hemoglobin A1c, and 
dialysis duration. Also, there is no difference in body mass in-
dex (BMI) at baseline and 12 months in both groups. In com-
parison to baseline BMI, BMI at 12 months decreased in both 
no PTDM and PTDM group. Compared with the no PTDM 
group, recipients with PTDM were significantly older (P=  
0.002) and exhibited a significantly higher prevalence of predia-
betes at baseline OGTT (P=0.05). Acute rejection occurred in 
two no PTDM recipients and in five recipients with PTDM (P=  
0.013). Rejection episodes occurred within 3 months of trans-
plantation in three recipients, all of whom were diagnosed with 
PTDM at 3 months. At baseline, fasting plasma glucose, 2-hour 
plasma glucose, fasting plasma insulin level, HOMA-IR, and 
IGI30 did not significantly differ between groups. Donor charac-
teristics including age, sex, and donation type did not signifi-
cantly differ between groups. During the study period, the tacro-
limus trough level was maintained within the target range in 
both groups (Supplemental Fig. S1). No graft failures or patient 
deaths occurred during the study and graft function was well 
maintained in both groups at 1 year after transplantation (data 
not shown). 
Trajectories of insulin resistance and secretion
Changes in IGI30 and HOMA-IR were measured at 3-month in-
tervals to determine the trajectories of insulin resistance and se-
cretion associated with PTDM (Table 2). The pre-transplanta-
tion levels of insulin resistance (HOMA-IR) and insulin secre-
tion (IGI30) did not significantly differ between the no PTDM 
and PTDM groups (1.33 [1.03 to 1.63] vs. 1.76 [1.05 to 2.32], 
P=0.348 in HOMA-IR; 0.67 [0.4 to 0.91] vs. 0.52 [0.31 to 
1.19], P>0.999 in IGI30). Compared with baseline result, 
HOMA-IR of every 3-month interval results significantly in-
creased in both groups based on post-hoc analysis (P<0.05 in 
all post hoc analysis results). In addition, significant changes 
throughout the study period were seen in both groups (P<0.001 
in both groups). There were significant differences of HOMA-
IR between no PTDM and PTDM groups at 6 and 9 months 
OGTTs, whereas no significant differences were seen at 3 and 
12 months OGTTs (2.41 [1.91 to 3.48] vs. 3.74 [2.27 to 6.73], 
P=0.078 in 3 months; 2.34 [1.74 to 3.36] vs. 3.69 [2.57 to 4.40], 
P=0.012 in 6 months; 1.89 [1.41 to 2.38] vs. 2.48 [1.84 to 4.24], 
P=0.033 in 9 months; 2.06 [1.52 to 2.65] vs. 2.72 [1.88 to 5.21], 
P=0.078 in 12 months) (Fig. 3A). 
In IGI30, every 3-month interval results significantly increased 
comparing to baseline result in no PTDM group (all P values 
were <0.05). However, in PTDM group, every 3-month interval 
results showed that IGI30 decreased comparing to baseline result 
without significant changes (all P values were >0.05). These 
changes were significant in both groups (P<0.001 in no PTDM 
group, P=0.008 in PTDM group). In addition, there were sig-
nificant differences of every IGI30 result between two groups 
(1.02 [0.57 to 1.78] vs. 0.33 [0.22 to 0.56], P<0.001 in 3 
months; 0.96 [0.48 to 1.70] vs. 0.30 [0.21 to 0.63], P<0.001 in 
6 months; 1.05 [0.48 to 1.59] vs. 0.38 [0.24 to 0.70], P=0.010 
in 9 months; 0.93 [0.54 to 2.05] vs. 0.37 [0.06 to 0.60], P<0.001 
Fig. 2. Incidence of post-transplant diabetes mellitus (PTDM) dur-
ing 1 year after transplantation. About 87% of PTDM was diag-
nosed during the first 6 months after transplantation, and no PTDM 
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in 12 months) (Fig. 3B). As a result, HOMA-IR increased in 
both groups, whereas IGI30 decreased in PTDM group and in-
creased in no PTDM group. 
In additional analysis, Matsuda index of every 3-month inter-
val results decreased compared to baseline result in both groups. 
Matsuda index results of PTDM group were significantly lower 
than no PTDM group at 3, 6, and 9 months OGTTs. This result 
was in keeping with HOMA-IR results. In Secr1PH, every 
3-month interval results increased in no PTDM group compared 
to baseline result. However, Secr1PH decreased in PTDM group 
compared to baseline result. In addition, Secr1PH results at 3, 6, 
and 9 months showed significantly differences between no 
PTDM and PTDM groups (Supplemental Table S1). These re-
sults of additional analysis were supporting main results that 
impairment of insulin secretion did not compensate increased 
insulin resistance.
PTDM risk factors
At baseline, age, prediabetes status, and acute rejection episodes 
significantly differed between groups. Table 3 shows the odds 
ratios for risk factors assessed by multivariate logistic regres-
sion analysis. Both univariate and multivariate analyses re-
vealed that age, prediabetes status, and acute rejection episodes 
were associated with an increased risk of PTDM. Baseline 
HOMA-IR and IGI30 values were not significantly associated 
with the development of PTDM. 
DISCUSSION
Our multicenter cohort study of kidney transplant recipients re-
ceiving a tacrolimus-based immunosuppressive regimen found 
that the 1-year cumulative incidence of PTDM was 26.4%, 
while the prevalence of PTDM was 9.2% at 12 months. Further-
more, insulin resistance increased immediately after transplan-
Table 1. Baseline Demographic and Clinical Characteristics of No PTDM and PTDM Groups
Variable No PTDM (n=64) PTDM (n=23) P value
Age, yr 42.9±9.4 50.1±9.1 0.002
Recipient sex (male) 36 (56) 14 (61) 0.808
Body mass index at baseline, kg/m2 22.6±3.1 23.7±3.8 0.143
Body mass index at 12 months, kg/m2 22.5±2.8 23.0±3.3 0.460
Systolic blood pressure, mm Hg 140.2±20.2 140.6±13.6 0.931
Diastolic blood pressure, mm Hg 87.2±14.7 87.6±10.5 0.890
Prediabetes 31 (48) 17 (74) 0.050
HbA1c, % 5.0±0.5 5.1±0.5 0.409
Dialysis duration, mo 13.5 (0–80.5) 19 (3–69) 0.698
Acute rejection 2 (3.1) 5 (21.7) 0.013
Acute rejection within 3 months 0 3 (13.0) 0.017
Baseline OGTT results
Fasting plasma glucose, mg/dL 86 (82.3–92.8) 87 (82–97) 0.558
2-hour plasma glucose, mg/dL 138 (121.3–156) 163 (118–173) 0.112
Fasting plasma insulin, µIU/mL 6.5 (4.8–7.7) 7.7 (4.8–11.4) 0.097
HOMA-IR 1.33 (1.03–1.63) 1.76 (1.05–2.32) 0.348
IGI30 0.67 (0.4–0.91) 0.52 (0.31–1.19) >0.999
Total cholesterol, mg/dL 158.7±29.9 157.2±28.1 0.831
Steroid maintenance at 12 months 31 (48) 7 (30) 0.151
Donor age, yr 43.3±13.6 46.0±12.4 0.461
Donor sex (male) 37 (58) 12 (52) 0.807
Living donor 41 (64) 13 (57) 0.618
Values are expressed as mean±standard deviation, number (%), or median (interquartile range).   
PTDM, post-transplant diabetes mellitus; HbA1c, hemoglobin A1c; OGTT, oral glucose tolerance test; HOMA-IR, homeostatic model assessment for 
insulin resistance; IGI30, insulinogenic index.
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Table 2. Comparisons of HOMA-IR and IGI30 According to Group and Measurement Time
Variable No PTDM (n=64) PTDM (n=23) P valuea
HOMA-IR
Baseline 1.33 (1.03–1.63) 1.76 (1.05–2.32) 0.348
3 months 2.41 (1.91–3.48) 3.74 (2.27–6.73) 0.078
6 months 2.34 (1.74–3.36) 3.69 (2.57–4.40) 0.012
9 months 1.89 (1.41–2.38) 2.48 (1.84–4.24) 0.033
12 months 2.06 (1.52–2.65) 2.72 (1.88–5.21) 0.078
P valueb <0.001 <0.001
Post hoc analysisc
Baseline vs. 3 months <0.001 <0.001
Baseline vs. 6 months <0.001 <0.001
Baseline vs. 9 months <0.001 0.007
Baseline vs. 12 months <0.001 0.005
IGI30
Baseline 0.67 (0.4–0.91) 0.52 (0.31–1.19) >0.999
3 months 1.02 (0.57–1.78) 0.33 (0.22–0.56) <0.001
6 months 0.96 (0.48–1.70) 0.30 (0.21–0.63) <0.001
9 months 1.05 (0.48–1.59) 0.38 (0.24–0.70) 0.010
12 months 0.93 (0.54–2.05) 0.37 (0.26–0.60) <0.001
P valueb <0.001 0.008
Post hoc analysisc
Baseline vs. 3 months <0.001 0.085
Baseline vs. 6 months 0.002 0.177
Baseline vs. 9 months 0.020 >0.999
Baseline vs. 12 months <0.001 0.660
Values are expressed as median (interquartile range).   
HOMA-IR, homeostatic model assessment for insulin resistance; IGI30, insulinogenic index; PTDM, post-transplant diabetes mellitus.
aP values are obtained by using Mann-Whitney U test and corrected using the Bonferroni adjustment, which are significant when <0.05; bP values are 
obtained by using the Friedman rank sum test; cData are P values, which are obtained by using Wilcoxon signed-rank test and corrected using the Bonfer-
roni adjustment, which are significant when <0.05.
Fig. 3. Trajectories of insulin resistance and secretion during 1 year after kidney transplantation in both groups. (A) A trend of homeostasis 
model assessment of insulin resistance (HOMA-IR) levels showed that insulin resistance increased after transplantation in no post-trans-
plant diabetes mellitus (PTDM) and PTDM groups. (B) Insulinogenic index (IGI30) in no PTDM group increased after transplantation; how-
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tation and peaked 3 months after transplantation in all recipi-
ents. Notably, no PTDM recipients showed a compensatory in-
crease in insulin secretion, while the levels of secreted insulin 
were slightly reduced in the PTDM group. The risk factors sig-
nificantly associated with the development of PTDM in kidney 
transplant recipients were older age, prediabetes, and acute re-
jection episodes. The trajectory analysis revealed that insulin re-
sistance increased after transplantation in both groups; however, 
insulin secretion did not increase to compensate for the increase 
in insulin resistance in recipients with PTDM, suggesting that 
failure of beta cells to compensate in early post-transplantation 
period plays a critical role in the development of PTDM in 
Asian kidney transplant recipients.
The reported 1-year incidence of PTDM in kidney transplant 
recipients varies between 9% and 39% [21]. This disparity is re-
lated to several factors, including immunosuppressive regimens, 
diagnostic criteria and timing, and the ethnicity and heterogene-
ity of recipients. In our study, the 1-year cumulative incidence 
of PTDM was estimated from pre-transplant baseline and post-
transplantation (at 3-month intervals) OGTTs. At 3 months after 
transplantation, the incidence of PTDM was 14.9%, which con-
stituted more than half of the 1-year cumulative incidence 
(56.5%). At 6 months after transplantation, the cumulative inci-
dence of PTDM was 22.9%, which constituted 86.9% of the 
1-year cumulative incidence of PTDM. These findings are con-
sistent with the results of a previous study, which showed that 
the incidence of PTDM was high in the first months after trans-
plantation, and then increased slowly [8]. Furthermore, glucose 
metabolism improved within 1 year after transplantation in 15 
of the 23 recipients who developed PTDM. This finding is con-
sistent with the results of a previous study, which demonstrated 
that the absolute incidences of PTDM were 20% at 2 months 
post-transplantation and 10% at 1 year after transplantation in 
recipients receiving a tacrolimus-based regimen [22]. Based on 
the serial OGTT results, no cases of new-onset PTDM occurred 
between 9 and 12 months after surgery, highlighting the impor-
tance of monitoring for PTDM in kidney transplant recipients 
during the first 6 months after transplantation.
In the present study, we performed a baseline pre-transplanta-
tion OGTT to identify pre-existing impairments in glucose me-
tabolism. The baseline OGTT revealed that 33 patients (18.4%) 
had undiagnosed diabetes; these patients were excluded from 
the final analysis. Caillard et al. [23] reported that 3.2% of the 
recipients were excluded from their study due to diabetes re-
vealed by pre-transplantation OGTT. Taken together, these find-
ings suggest that without a baseline OGTT, the incidence of 
PTDM may be high due to pre-existing diabetes before trans-
plantation. Therefore, the 1-year incidence of PTDM reported 
in our study may be more accurate than the incidences reported 
in previous similar studies [7,19,22]. 
We traced trajectories of insulin secretion and resistance and 
compared those at each time point between two groups. Insulin 
resistance increased in both groups but, more significantly in-
creased in PTDM group at only 6 and 9 months after kidney 
transplantation compared with no PTDM group. Meanwhile in-
sulin secretory function did not increase to overcome the in-
creased insulin resistance and were consistently lower in PTDM 
group at 3, 6, and 9 months when new PTDM cases were diag-
nosed. At 3 months after kidney transplantation, when more 
than half of the PTDM developed, PTDM group had signifi-
cantly lower insulin secretion but, similar insulin resistance 
compared with the no PTDM group. These suggest that the de-
fect in insulin secretory compensation for the increase in insulin 
resistance is underlying mechanism in the development of 
PTDM during the first year after kidney transplantation. A pre-
vious large-scale cohort study concluded that insufficient com-
pensation for reduced insulin sensitivity, due to impaired insulin 
secretory function, was a crucial factor in the deterioration of 
Table 3. Logistic Regression Analysis of Risk Factors Associated with Post-Transplant Diabetes Mellitus 
Variables Unadjusted OR P value Adjusted OR P value
Age 1.09 (1.03–1.16) 0.004 1.17 (1.07–1.28) 0.001
Male sex 1.21 (0.46–3.19) 0.701 1.10 (0.27–4.49) 0.886
BMI, kg/m2 1.11 (0.96–1.29) 0.146 1.06 (0.88–1.28) 0.532
Prediabetes 3.02 (1.05–8.64) 0.040 4.09 (1.01–16.61) 0.048
Acute rejection 8.61 (1.54–48.17) 0.014 75.9 (2.9–1,940.5) 0.009
HOMA-IR at baseline 1.26 (0.78–1.96) 0.369 0.68 (0.36–1.31) 0.254
IGI30 at baseline 1.16 (0.81–1.66) 0.426 1.41 (0.81–2.45) 0.222
OR, odds ratio; BMI, body mass index; HOMA-IR, homeostatic model assessment for insulin resistance; IGI, insulinogenic index.
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glucose tolerance in a general Asian population [24]. Moreover, 
several previous studies have found that impaired insulin secre-
tory function was a major contributing factor in the develop-
ment of PTDM in kidney transplant recipients. To the best of 
our knowledge, our study is the first to show the trajectories of 
insulin secretion and insulin resistance during the first year after 
kidney transplantation. There were several previous studies that 
evaluate insulin secretion and resistance in focused on long-
term manner. However, it is important to evaluate insulin secre-
tion and resistance trajectories during the first year after kidney 
transplantation because the majority of PTDM occurred during 
the early period of post-transplantation [19,25,26]. A major 
strength of our study is that we estimated insulin secretion and 
insulin resistance using several measurements derived from the 
OGTT. HOMA-IR and IGI30 are more accurate reflections of 
glucose and insulin metabolism, compared to measurements of 
basal values alone.
We found that HOMA-IR increased and peaked 3 months af-
ter transplantation in recipients with PTDM and no PTDM re-
cipients, then remained at similar levels after 3 months. This 
pattern might be associated with the dose of steroid, which was 
administrated intensely in early period of transplantation and ta-
pered during 1-year after transplantation. IGI30 tended to de-
crease in recipients with PTDM, whereas the values increased 
from baseline to 3 months in recipients with no PTDM. These 
findings suggest that, unlike the progressive deterioration of in-
sulin secretion and sensitivity typical of type 2 diabetes melli-
tus, PTDM results from dynamic changes in glucose metabo-
lism in the early post-transplantation period, as well as changes 
in immunosuppressive drug doses and acute rejection episodes 
that typically occur within 6 months after transplantation [27]. 
As a result, post-transplantation changes in insulin secretion and 
resistance occur in the early post-transplantation period; recipi-
ents with reduced insulin secretory function are predisposed to 
PTDM. 
In terms of immunosuppression, changes in insulin secretion 
were primarily associated with calcineurin inhibitors (e.g., ta-
crolimus and cyclosporine), whereas insulin resistance was re-
lated to corticosteroid use [28,29]. Given that insulin secretion 
plays a primary role in the development of PTDM, the effect of 
calcineurin inhibitors may be more important than the effect of 
corticosteroids in the early post-transplantation period. Howev-
er, we found no significant relationship between the tacrolimus 
trough level and development of PTDM. The results of a previ-
ous long-term follow-up study suggested that insulin resistance 
associated with corticosteroid use was the deciding factor be-
tween the development of PTDM and improved glucose metab-
olism [27]. Further studies of the relationship between immuno-
suppressive agents and development of PTDM are needed to 
clarify the pathogenesis of PTDM in transplant recipients. 
Our findings of risk factors for PTDM (i.e., older age, predia-
betes at the time of transplantation, and at least one acute rejec-
tion episode) are consistent with those of previous reports [30], 
and we did not identify any novel risk factors. The baseline lev-
els of HOMA-IR and IGI30 did not differ between the PTDM 
and no PTDM groups. The mean variations in HOMA-IR and 
IGI30 from baseline to 12 months were significantly associated 
with the development of PTDM. We propose that the 1-year tra-
jectories of insulin secretion and insulin resistance may corre-
spond more closely with the development of PTDM in the late 
post-transplantation period. 
Our study had some limitations. First, we lacked data regard-
ing family history of diabetes and smoking status, which are po-
tential risk factors for PTDM. Second, our study population was 
relatively small, compared with similar studies using OGTTs in 
kidney transplant recipients [31,32]. However, our study popu-
lation was ethnically homogeneous, all patients were receiving 
the same immunosuppression regimen, and the results involved 
modern kidney transplantation, which may offset the limitations 
of our relatively small sample. 
In conclusion, our study of transplant recipients receiving a 
tacrolimus-based immunosuppressive regime revealed that in-
sulin secretion was significantly impaired in transplant recipi-
ents who developed PTDM, compared with no PTDM recipi-
ents. These findings suggest that impaired insulin secretory 
function played a more important role in the development of 
PTDM in the first year after transplantation, compared with in-
sulin resistance. Moreover, the cumulative incidence of PTDM 
was 26.4% at 1 year after kidney transplantation, whereas most 
patients developed PTDM during the first 6 months after trans-
plantation. We propose that it is feasible to identify recipients at 
risk of PTDM by performing regular OGTTs during the first 
year after kidney transplantation. 
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